Free Trial
NASDAQ:SILO

Silo Pharma (SILO) Stock Price, News & Analysis

Silo Pharma logo
$0.68 -0.02 (-2.49%)
As of 11:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Silo Pharma Stock (NASDAQ:SILO)

Key Stats

Today's Range
$0.67
$0.69
50-Day Range
$0.43
$0.69
52-Week Range
$0.41
$3.37
Volume
81,453 shs
Average Volume
1.85 million shs
Market Capitalization
$3.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Silo Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

SILO MarketRank™: 

Silo Pharma scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Silo Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Silo Pharma is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Silo Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Silo Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    5.66% of the float of Silo Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Silo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Silo Pharma does not currently pay a dividend.

  • Dividend Growth

    Silo Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.66% of the float of Silo Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Silo Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Silo Pharma has recently decreased by 56.89%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for SILO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Silo Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,300.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.37% of the stock of Silo Pharma is held by insiders.

  • Percentage Held by Institutions

    Only 5.58% of the stock of Silo Pharma is held by institutions.

  • Read more about Silo Pharma's insider trading history.
Receive SILO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silo Pharma and its competitors with MarketBeat's FREE daily newsletter.

SILO Stock News Headlines

Silo Pharma (NASDAQ:SILO) Raised to "Sell" at Wall Street Zen
Trump’s $100 Trillion Land Rush Is On
What Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.
See More Headlines

SILO Stock Analysis - Frequently Asked Questions

Silo Pharma's stock was trading at $0.89 at the beginning of the year. Since then, SILO stock has decreased by 23.9% and is now trading at $0.6770.

Silo Pharma, Inc. (NASDAQ:SILO) released its earnings results on Friday, May, 9th. The company reported ($0.23) EPS for the quarter. The company had revenue of $0.02 million for the quarter. Silo Pharma had a negative net margin of 6,420.83% and a negative trailing twelve-month return on equity of 84.88%.

Shares of SILO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Silo Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Citius Pharmaceuticals (CTXR), Sunshine Biopharma (SBFM), AbbVie (ABBV) and Biorestorative Therapies (BRTX).

Company Calendar

Last Earnings
5/09/2025
Today
7/24/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Apparel
Current Symbol
NASDAQ:SILO
CIK
1514183
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.39 million
Net Margins
-6,420.83%
Pretax Margin
-6,419.44%
Return on Equity
-84.88%
Return on Assets
-61.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.73
Quick Ratio
4.73

Sales & Book Value

Annual Sales
$70 thousand
Price / Sales
44.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.12 per share
Price / Book
0.62

Miscellaneous

Outstanding Shares
4,480,000
Free Float
4,288,000
Market Cap
$3.11 million
Optionable
Not Optionable
Beta
0.29
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SILO) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners